688321 微芯生物
已收盘 09-11 15:00:00
资讯
新帖
简况
每周股票复盘：微芯生物（688321）半年报营收增33.60%
证券之星 · 02:17
每周股票复盘：微芯生物（688321）半年报营收增33.60%
股市必读：微芯生物新发布《国投证券股份有限公司关于深圳微芯生物科技股份有限公司2026年半年度持续督导跟踪报告》
证券之星 · 09-10
股市必读：微芯生物新发布《国投证券股份有限公司关于深圳微芯生物科技股份有限公司2026年半年度持续督导跟踪报告》
每周股票复盘：机构净卖出微芯生物（688321）1112.09万元
证券之星 · 09-06
每周股票复盘：机构净卖出微芯生物（688321）1112.09万元
9月3日微芯生物现1笔大宗交易 机构净卖出1112.09万元
证券之星 · 09-03
9月3日微芯生物现1笔大宗交易 机构净卖出1112.09万元
微芯生物（688321）3513.31万股限售股将于9月2日解禁，占总股本7.93%
证券之星 · 09-02
微芯生物（688321）3513.31万股限售股将于9月2日解禁，占总股本7.93%
【机构调研记录】长城基金调研诺 普 信、微芯生物等4只个股（附名单）
证券之星 · 08-24
【机构调研记录】长城基金调研诺 普 信、微芯生物等4只个股（附名单）
【机构调研记录】华宝基金调研微芯生物、莱尔科技等5只个股（附名单）
证券之星 · 08-24
【机构调研记录】华宝基金调研微芯生物、莱尔科技等5只个股（附名单）
【机构调研记录】先锋基金调研微芯生物
证券之星 · 08-24
【机构调研记录】先锋基金调研微芯生物
股市必读：微芯生物（688321）8月21日披露最新机构调研信息
证券之星 · 08-24
股市必读：微芯生物（688321）8月21日披露最新机构调研信息
微芯生物：8月20日进行路演，东吴证券、招商证券等多家机构参与
证券之星 · 08-21
微芯生物：8月20日进行路演，东吴证券、招商证券等多家机构参与
微芯生物（688321）2026年中报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 08-21
微芯生物（688321）2026年中报简析：营收净利润同比双双增长，应收账款上升
图解微芯生物中报：第二季度单季净利润同比下降11.57%
证券之星 · 08-20
图解微芯生物中报：第二季度单季净利润同比下降11.57%
微芯生物(688321.SH)发布半年度业绩，归母净利润7138.06万元，同比增长141.21%
智通财经 · 08-19
微芯生物(688321.SH)发布半年度业绩，归母净利润7138.06万元，同比增长141.21%
微芯生物(688321)6月30日股东户数2.56万户，较上期减少2.72%
证券之星 · 08-19
微芯生物(688321)6月30日股东户数2.56万户，较上期减少2.72%
每周股票复盘：微芯生物（688321）将召开2026年半年度业绩说明会
证券之星 · 08-16
每周股票复盘：微芯生物（688321）将召开2026年半年度业绩说明会
股市必读：微芯生物新发布《关于召开2026年半年度业绩说明会的公告》
证券之星 · 08-14
股市必读：微芯生物新发布《关于召开2026年半年度业绩说明会的公告》
微芯生物（688321）披露2026年半年度业绩说明会召开安排，8月12日股价上涨0.03%
证券之星 · 08-12
微芯生物（688321）披露2026年半年度业绩说明会召开安排，8月12日股价上涨0.03%
8月7日微芯生物涨9.74%，建信中证1000指数增强A基金重仓该股
证券之星 · 08-07
8月7日微芯生物涨9.74%，建信中证1000指数增强A基金重仓该股
股市必读：微芯生物新发布《深圳微芯生物科技股份有限公司董事会薪酬与考核委员会关于2026年限制性股票激励计划首次授予及预留授予（第一批次）部分激励对象名单的核查意见》
证券之星 · 08-06
股市必读：微芯生物新发布《深圳微芯生物科技股份有限公司董事会薪酬与考核委员会关于2026年限制性股票激励计划首次授予及预留授予（第一批次）部分激励对象名单的核查意见》
微芯生物最新公告：注射用NW001临床试验申请获国家药监局受理
证券之星 · 08-05
微芯生物最新公告：注射用NW001临床试验申请获国家药监局受理
加载更多
公司概况
公司名称：
深圳微芯生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2019-08-12
主营业务：
深圳微芯生物科技股份有限公司的主营业务是药物技术开发、相关成果商业应用；新药研究、开发、技术转让及其它有关的服务；新治疗技术研究、开发、技术转让及其它有关的服务；对外专利、技术的许可授权；药品的生产；保健食品生产经营。公司的主要产品是西达本胺、西格列他钠、西奥罗尼、CS23546、CS231295、CS32582、CS08399、CS43158、NW001、CS12088、CS12192。公司是国家级专精特新“小巨人”企业。
发行价格：
20.43
{"stockData":{"symbol":"688321","market":"SH","secType":"STK","nameCN":"微芯生物","latestPrice":23.68,"timestamp":1789110000000,"preClose":24.5,"halted":0,"volume":8837354,"delay":0,"changeRate":-0.0335,"floatShares":443000000,"shares":443000000,"eps":0.2094,"marketStatus":"已收盘","change":-0.82,"latestTime":"09-11 15:00:00","open":24.48,"high":24.48,"low":23.44,"amount":210000000,"amplitude":0.0424,"askPrice":23.69,"askSize":50,"bidPrice":23.68,"bidSize":358,"shortable":0,"etf":0,"ttmEps":0.2094,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":5,"adr":0,"adjPreClose":24.5,"symbolType":"stock_kcb","openAndCloseTimeList":[[1789090200000,1789097400000],[1789102800000,1789110000000]],"highLimit":26.95,"lowLimit":22.05,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":442941642,"isCdr":false,"pbRate":4.32,"roa":"--","peRate":113.085005,"roe":"3.14%","epsLYR":0.125,"committee":0.302463,"marketValue":10489000000,"turnoverRate":0.02,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-09-14。","afterMarket":{"amount":47360,"volume":2000,"close":23.68,"buyVolume":200,"sellVolume":0,"time":1789112037746,"indexStatus":"已收盘 09-11 15:30:00","preClose":24.5},"floatMarketCap":10489000000},"requestUrl":"/m/hq/s/688321","defaultTab":"news","newsList":[{"id":"2667507188","title":"每周股票复盘：微芯生物（688321）半年报营收增33.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507188","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507188?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:17","pubTimestamp":1789237029,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，微芯生物报收于23.68元，较上周的25.18元下跌5.96%。本周，微芯生物9月7日盘中最高价报25.53元。来自公司公告汇总：2026年上半年微芯生物营业收入同比增长33.60%，净利润显著增长。交易信息汇总9月9日微芯生物发生1笔大宗交易，机构专用席位净卖出286.7万元。公司公告汇总国投证券股份有限公司发布关于深圳微芯生物科技股份有限公司2026年半年度持续督导跟踪报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666534466","title":"股市必读：微芯生物新发布《国投证券股份有限公司关于深圳微芯生物科技股份有限公司2026年半年度持续督导跟踪报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666534466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666534466?lang=zh_cn&edition=full","pubTime":"2026-09-10 01:07","pubTimestamp":1788973628,"startTime":"0","endTime":"0","summary":"公司公告汇总国投证券股份有限公司关于深圳微芯生物科技股份有限公司2026年半年度持续督导跟踪报告国投证券作为微芯生物2024年度向特定对象发行A股股票项目的保荐人，对2026年上半年持续督导情况进行报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000001818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665563366","title":"每周股票复盘：机构净卖出微芯生物（688321）1112.09万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665563366","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665563366?lang=zh_cn&edition=full","pubTime":"2026-09-06 03:23","pubTimestamp":1788636189,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，微芯生物（688321）报收于25.18元，较上周的25.83元下跌2.52%。本周，微芯生物9月4日盘中最高价报25.75元。9月2日盘中最低价报24.82元。微芯生物当前最新总市值111.53亿元，在化学制药板块市值排名42/149，在两市A股市值排名1646/5214。本周关注点来自交易信息汇总：9月3日微芯生物现1笔大宗交易，机构净卖出1112.09万元交易信息汇总9月3日微芯生物现1笔大宗交易，机构净卖出1112.09万元以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600001127.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664873901","title":"9月3日微芯生物现1笔大宗交易 机构净卖出1112.09万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664873901","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664873901?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:43","pubTimestamp":1788428587,"startTime":"0","endTime":"0","summary":"证券之星消息，9月3日微芯生物发生大宗交易，交易数据如下：大宗交易成交价格25.29元，成交43.97万股，成交金额1112.09万元，买方营业部为华泰证券股份有限公司无锡分公司，卖方营业部为机构专用。近三个月该股共发生1笔大宗交易，合计成交4397.0手。该股在过去半年内已有共计3513.31万股限售解禁股上市，占公司总股本的7.93%。截至2026年9月3日收盘，微芯生物报收于25.29元，上涨1.69%，换手率1.48%，成交量6.57万手，成交额1.65亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300032260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664862262","title":"微芯生物（688321）3513.31万股限售股将于9月2日解禁，占总股本7.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664862262","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664862262?lang=zh_cn&edition=full","pubTime":"2026-09-02 08:15","pubTimestamp":1788308152,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，微芯生物于9月2日将有3513.31万股限售股份解禁，为公司定向增发机构配售股份，占公司总股本7.93%。本次解禁后，公司已无限售股份。微芯生物主营业务：为患者提供可承受的、临床亟需的原创新分子实体药物,具备完整的从药物作用靶点发现与确证、先导分子的发现与评价到新药临床开发、产业化、学术推广及销售的能力。本文数据来源于微芯生物公告，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200007397.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661924136","title":"【机构调研记录】长城基金调研诺 普 信、微芯生物等4只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2661924136","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661924136?lang=zh_cn&edition=full","pubTime":"2026-08-24 08:02","pubTimestamp":1787529768,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月21日披露的机构调研信息，长城基金近期对4家上市公司进行了调研，相关名单如下：1）诺 普 信 调研纪要：25/26产季产量符合期初预期，产季提前约二至三周结束。田田圈公司逐步缩减控股经销商数量，截至2026年6月30日仅剩余11家。4）德赛西威 个股亮点：公司正式发布机器人智能基座AI Cube，并荣获金球奖认证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400002557.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661241358","title":"【机构调研记录】华宝基金调研微芯生物、莱尔科技等5只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2661241358","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661241358?lang=zh_cn&edition=full","pubTime":"2026-08-24 08:01","pubTimestamp":1787529704,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月21日披露的机构调研信息，华宝基金近期对5家上市公司进行了调研，相关名单如下：1）微芯生物 调研纪要：西格列他钠凭借“降糖、调脂、利肝、安心”综合获益优势，连续几年实现翻倍式增长。液体鼻喷流感疫苗于7月获批，8月初上市销售。水痘疫苗出口收入2,759.06万元，同比增长184.27%。2026年7月24日，公司正式获证监会批复，同意发行股份及支付现金收购易介医疗100%股权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400002488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0214","688683","BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661413552","title":"【机构调研记录】先锋基金调研微芯生物","url":"https://stock-news.laohu8.com/highlight/detail?id=2661413552","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661413552?lang=zh_cn&edition=full","pubTime":"2026-08-24 08:01","pubTimestamp":1787529696,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月21日披露的机构调研信息，先锋基金近期对1家上市公司进行了调研，相关名单如下：1）微芯生物 调研纪要：西格列他钠凭借“降糖、调脂、利肝、安心”综合获益优势，连续几年实现翻倍式增长。先锋基金成立于2016年，截至目前，资产管理规模37.89亿元，排名159/212；资产管理规模26.24亿元，排名140/212；管理公募基金数18只，排名139/212；旗下公募基金经理6人，排名132/212。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400002478.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661243077","title":"股市必读：微芯生物（688321）8月21日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2661243077","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661243077?lang=zh_cn&edition=full","pubTime":"2026-08-24 01:36","pubTimestamp":1787506572,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，微芯生物报收于27.95元，下跌6.68%，换手率5.12%，成交量20.89万手，成交额5.95亿元。当日关注点交易信息汇总：8月21日主力资金净流出1790.66万元，占总成交额3.01%。机构调研要点：CS231295中国I期临床已在胶质母细胞瘤患者中观察到疗效信号，美国I期已完成首例入组。机构调研要点：NW001于8月5日获IND受理，预计60个工作日内默许启动临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400000939.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661426420","title":"微芯生物：8月20日进行路演，东吴证券、招商证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2661426420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661426420?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:29","pubTimestamp":1787308188,"startTime":"0","endTime":"0","summary":"公司与HUYBIO将根据已签订的协议约定进行西达本胺相关的商业收入分成，如后续触发相关节点，公司将及时进行信息披露。答：NW001已于8月5日收到IND受理通知书，如无意外，预计60个工作日后即可默许启动临床试验。该股最近90天内共有2家机构给出评级，买入评级1家，增持评级1家。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100034679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1147","BK0009","601555","688321","06099","BK0028","BK0188","BK0239","BK0183","BK0012","BK0276","BK1564","600999","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661963230","title":"微芯生物（688321）2026年中报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2661963230","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661963230?lang=zh_cn&edition=full","pubTime":"2026-08-21 06:07","pubTimestamp":1787263657,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期微芯生物发布2026年中报。截至本报告期末，公司营业总收入5.43亿元，同比上升33.6%，归母净利润7138.06万元，同比上升141.21%。本报告期微芯生物应收账款上升，应收账款同比增幅达50.37%。合同负债变动幅度为483.81%,原因:报告期预收服务费增加。管理费用变动幅度为1.22%,原因:营业收入增长下，管理费用整体保持稳定。针对特定基因突变的患者也有一些靶向药物获批上市。本文数据来源于微芯生物2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100004755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660242276","title":"图解微芯生物中报：第二季度单季净利润同比下降11.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660242276","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660242276?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:13","pubTimestamp":1787159599,"startTime":"0","endTime":"0","summary":"证券之星消息，微芯生物2026年中报显示，上半年度公司主营收入5.43亿元，同比上升33.6%；归母净利润7138.06万元，同比上升141.21%；扣非净利润6470.18万元，同比上升218.41%；其中2026年第二季度，公司单季度主营收入2.86亿元，同比上升17.13%；单季度归母净利润4310.87万元，同比下降11.57%；单季度扣非净利润3905.77万元，同比下降13.02%；负债率44.56%，投资收益-1400.54万元，财务费用1678.42万元，毛利率86.33%。财报数据概要请见下图:本文数据来源于微芯生物2026年中报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000001503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660440505","title":"微芯生物(688321.SH)发布半年度业绩，归母净利润7138.06万元，同比增长141.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660440505","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660440505?lang=zh_cn&edition=full","pubTime":"2026-08-19 19:28","pubTimestamp":1787138926,"startTime":"0","endTime":"0","summary":"智通财经APP讯，微芯生物(688321.SH)披露2026年半年度报告，报告期公司实现营业收入5.43亿元，同比增长33.60%;归属于上市公司股东的净利润7138.06万元，同比增长141.21%;扣除非经常性损益的净利润6470.18万元，同比增长218.41%;基本每股收益0.1645元。报告期内，公司产品西格列他钠较去年上半年保持翻倍以上增长，且其八车间两条固体制剂生产线已于第二季度获得药品GMP符合性检查告知书，为下半年产能提供有力支撑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482122.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"微芯生物(688321.SH)发布半年度业绩，归母净利润7138.06万元，同比增长141.21%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660744441","title":"微芯生物(688321)6月30日股东户数2.56万户，较上期减少2.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660744441","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660744441?lang=zh_cn&edition=full","pubTime":"2026-08-19 18:02","pubTimestamp":1787133755,"startTime":"0","endTime":"0","summary":"证券之星消息，近日微芯生物披露，截至2026年6月30日公司股东户数为2.56万户，较3月31日减少716.0户，减幅为2.72%。在化学制药行业个股中，微芯生物股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.64万户。从股价来看，2026年3月31日至2026年6月30日，微芯生物区间跌幅为7.66%，在此期间股东户数减少716.0户，减幅为2.72%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900031514.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659671175","title":"每周股票复盘：微芯生物（688321）将召开2026年半年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2659671175","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659671175?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:32","pubTimestamp":1786815129,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，微芯生物报收于30.85元，较上周的29.74元上涨3.73%。本周，微芯生物8月13日盘中最高价报32.15元。8月10日盘中最低价报28.92元。微芯生物当前最新总市值136.65亿元，在化学制药板块市值排名35/149，在两市A股市值排名1397/5207。本周关注点公司公告汇总：微芯生物将于2026年8月20日召开半年度业绩说明会，介绍经营成果及财务状况。投资者可于2026年8月13日至8月19日16:00前通过上证路演中心网站或公司邮箱ir@chipscreen.com提交问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659611169","title":"股市必读：微芯生物新发布《关于召开2026年半年度业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2659611169","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659611169?lang=zh_cn&edition=full","pubTime":"2026-08-14 01:09","pubTimestamp":1786640952,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，微芯生物报收于31.17元，上涨1.73%，换手率4.69%，成交量19.12万手，成交额5.98亿元。公司公告汇总：微芯生物将于2026年8月20日召开2026年半年度业绩说明会，投资者可于8月13日至19日16:00前提交问题。公司公告汇总关于召开2026年半年度业绩说明会的公告深圳微芯生物科技股份有限公司将于2026年8月20日10:00-11:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司半年度经营成果及财务状况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081400000786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658905348","title":"微芯生物（688321）披露2026年半年度业绩说明会召开安排，8月12日股价上涨0.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658905348","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658905348?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:25","pubTimestamp":1786544718,"startTime":"0","endTime":"0","summary":"截至2026年8月12日收盘，微芯生物报收于30.64元，较前一交易日上涨0.03%，最新总市值为135.72亿元。该股当日开盘30.3元，最高31.17元，最低30.15元，成交额达4.38亿元，换手率为3.49%。公司将于2026年8月20日10:00-11:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司半年度经营成果及财务状况。投资者可于2026年8月13日至8月19日16:00前通过上证路演中心网站或公司邮箱ir@chipscreen.com提交问题。说明会结束后可通过该平台查看会议内容。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081200040211.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657816616","title":"8月7日微芯生物涨9.74%，建信中证1000指数增强A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657816616","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657816616?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:41","pubTimestamp":1786092101,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日微芯生物涨9.74%，收盘报29.74元，换手率6.12%，成交量24.97万手，成交额7.18亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为建信基金的建信中证1000指数增强A。建信中证1000指数增强A目前规模为8.27亿元，最新净值2.1327，较上一交易日上涨0.73%，近一年上涨17.79%。建信中证1000指数增强A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657248475","title":"股市必读：微芯生物新发布《深圳微芯生物科技股份有限公司董事会薪酬与考核委员会关于2026年限制性股票激励计划首次授予及预留授予（第一批次）部分激励对象名单的核查意见》","url":"https://stock-news.laohu8.com/highlight/detail?id=2657248475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657248475?lang=zh_cn&edition=full","pubTime":"2026-08-06 01:59","pubTimestamp":1785952764,"startTime":"0","endTime":"0","summary":"深圳微芯生物科技股份有限公司2026年限制性股票激励计划首次授予及预留授予部分激励对象名单本次授予权益总数为7,087,061股，其中首次授予6,846,000股，涉及177名激励对象；预留部分241,061股；实际控制人XIANPING LU获授4,429,000股；所有激励对象获授股票均未超过公司股本总额的1.00%，累计标的股票总数未超过公司股本总额的20.00%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001718.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688321","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657545844","title":"微芯生物最新公告：注射用NW001临床试验申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2657545844","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657545844?lang=zh_cn&edition=full","pubTime":"2026-08-05 18:40","pubTimestamp":1785926437,"startTime":"0","endTime":"0","summary":"微芯生物(688321.SH)公告称，公司与成都微芯新域生物技术有限公司合作研发的注射用NW001关于治疗晚期恶性肿瘤(实体瘤和淋巴瘤)的临床试验申请获得国家药监局药审中心受理。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080500036726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688321"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789267707356,"stockEarnings":[{"period":"1week","weight":-0.0596},{"period":"1month","weight":-0.2272},{"period":"3month","weight":-0.0622},{"period":"6month","weight":-0.2196},{"period":"1year","weight":-0.291},{"period":"ytd","weight":-0.1881}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":-0.0148},{"period":"3month","weight":-0.0356},{"period":"6month","weight":-0.0506},{"period":"1year","weight":0.0033},{"period":"ytd","weight":-0.0203}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳微芯生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"25565人(较上一季度减少2.72%)","perCapita":"17326股","listingDate":"2019-08-12","address":"广东省深圳市南山区西丽街道曙光社区智谷产业园B栋21F-24F","registeredCapital":"44294万元","survey":" 深圳微芯生物科技股份有限公司的主营业务是药物技术开发、相关成果商业应用；新药研究、开发、技术转让及其它有关的服务；新治疗技术研究、开发、技术转让及其它有关的服务；对外专利、技术的许可授权；药品的生产；保健食品生产经营。公司的主要产品是西达本胺、西格列他钠、西奥罗尼、CS23546、CS231295、CS32582、CS08399、CS43158、NW001、CS12088、CS12192。公司是国家级专精特新“小巨人”企业。","listedPrice":20.43},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"微芯生物,688321,微芯生物股票,微芯生物股票老虎,微芯生物股票老虎国际,微芯生物行情,微芯生物股票行情,微芯生物股价,微芯生物股市,微芯生物股票价格,微芯生物股票交易,微芯生物股票购买,微芯生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"微芯生物(688321)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供微芯生物(688321)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}